Antiplatelet Therapy for Secondary Stroke Prevention in Patients with Ischemic Stroke or Transient Ischemic Attack

Abstract

The risk of stroke recurrence is highest in the acute phase after transient ischemic attack (TIA) or ischemic stroke. Therefore, patients with TIA or ischemic stroke should be treated with antiplatelet medication for stroke prevention. The short-term use of dual antiplatelet therapy between 21 and 90 days may be considered in those with acute minor stroke or TIA and highrisk of recurrence. However, the long-term use of dual antiplatelet therapy is not recommended due to the risk of bleeding. The current stroke guideline does not specify the administration of an antiplatelet for the secondary prevention of ischemic stroke. However, as clinical studies progress, antiplatelet therapy may become a personalized treatment in the future.

Related Papers

• → Differentiating ischemic stroke subtypes: Risk factors and secondary prevention(2009)65 cited
• A GEOMETRIC MEAN IN THE FURUTA INEQUALITY(2002)
• → Antiplatelets in Stroke Prevention(2014)13 cited
• [New form of a acetylsalicylic acid in the secondary prevention of ischemic stroke].(2013)
• → Antiplatelet Therapy for Secondary Stroke Prevention in Patients with Ischemic Stroke or Transient Ischemic Attack(2021)